Investment Banking

Centerview wins roles on $5bn of cancer-drug deals

Two multibillion-dollar deals will aid the US investment bank as it aims for the top spot in Dealogic’s boutique rankings

Centerview Partners, the US investment bank boutique, has won a role on two multibillion-dollar cancer-drug deals announced on December 9, advising the target company on both.

Sanofi, the French pharmaceutical company, announced it had agreed to acquire Synthorx, a biotech that specialises in cancer treatments, for $2.5bn in cash. Morgan Stanley, the US bank, is acting as financial adviser to Sanofi, while Centerview is exclusive adviser to Synthorx.

WSJ Logo
Ray Dalio Sells Last Stake in Bridgewater, the Hedge Fund That Made Him a BillionaireExternal link

Ray Dalio Sells Last Stake in Bridgewater, the Hedge Fund That Made Him a Billionaire